Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
HIV Seropositivity: HELP
Articles by Una O'Doherty
Based on 2 articles published since 2009
(Why 2 articles?)
||||

Between 2009 and 2019, U. O'Doherty wrote the following 2 articles about HIV Seropositivity.
 
+ Citations + Abstracts
1 Clinical Trial Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs. 2017

Tapia, G / Højen, J F / Ökvist, M / Olesen, R / Leth, S / Nissen, S K / VanBelzen, D J / O'Doherty, U / Mørk, A / Krogsgaard, K / Søgaard, O S / Østergaard, L / Tolstrup, M / Pantaleo, G / Sommerfelt, M A. ·Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, BH10-527, CH-1011 Lausanne, Switzerland. · Department of Infectious Diseases, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark. · Bionor Pharma AS, P.O.Box 1477 Vika, NO-0116 Oslo, Norway. · University of Pennsylvania, Philadelphia, 19104 PA, USA. · Bionor Pharma AS, P.O.Box 1477 Vika, NO-0116 Oslo, Norway. Electronic address: ms@bionorpharma.com. ·J Infect · Pubmed #28917661.

ABSTRACT: OBJECTIVES: The REDUC clinical study Part B investigated Vacc-4x/rhuGM-CSF therapeutic vaccination prior to HIV latency reversal using romidepsin. The main finding was a statistically significant reduction from baseline in viral reservoir measurements. Here we evaluated HIV-specific functional T-cell responses following Vacc-4x/rhuGM-CSF immunotherapy in relation to virological outcomes on the HIV reservoir. METHODS: This study, conducted in Aarhus, Denmark, enrolled participants (n = 20) with CD4>500 cells/mm RESULTS: The frequency of participants with CD8+ T-cell proliferation assay positivity was 8/16 (50%) at baseline, 11/15 (73%) post-vaccination, 6/14 (43%) during romidepsin, and 9/15 (60%)post-romidepsin. Participants with CD8+ T-cell proliferation assay positivity post-vaccination showed reductions in total HIV DNA post-vaccination (p = 0.006; q = 0.183), post-latency reversal (p = 0.005; q = 0.183), and CA-RNA reductions post-vaccination (p = 0.015; q = 0.254). Participants (40%) were defined as proliferation 'Responders' having ≥2-fold increase in assay positivity post-baseline. Robust ELISpot baseline responses were found in 87.5% participants. No significant changes were observed in the proportion of polyfunctional CD8+ T-cells to HIV CONCLUSIONS: In this 'shock and kill' approach supported by therapeutic vaccination, CD8+ T-cell proliferation represents a valuable means to monitor functional immune responses as part of the path towards functional HIV cure.

2 Article Comprehensive analysis of unique cases with extraordinary control over HIV replication. 2012

Mendoza, Daniel / Johnson, Sarah A / Peterson, Bennett A / Natarajan, Ven / Salgado, Maria / Dewar, Robin L / Burbelo, Peter D / Doria-Rose, Nicole A / Graf, Erin H / Greenwald, Jamieson H / Hodge, Jessica N / Thompson, William L / Cogliano, Nancy A / Chairez, Cheryl L / Rehm, Catherine A / Jones, Sara / Hallahan, Claire W / Kovacs, Joseph A / Sereti, Irini / Sued, Omar / Peel, Sheila A / O'Connell, Robert J / O'Doherty, Una / Chun, Tae-Wook / Connors, Mark / Migueles, Stephen A. ·Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA. ·Blood · Pubmed #22490332.

ABSTRACT: True long-term nonprogressors (LTNPs)/elite controllers (ECs) maintain durable control over HIV replication without antiretroviral therapy. Herein we describe 4 unique persons who were distinct from conventional LTNPs/ECs in that they had extraordinarily low HIV burdens and comparatively weak immune responses. As a group, typical LTNPs/ECs have unequivocally reactive HIV-1 Western blots, viral loads below the lower threshold of clinical assays, low levels of persistent viral reservoirs, an over-representation of protective HLA alleles, and robust HIV-specific CD8(+) T-cell responses. The 4 unique cases were distinguished from typical LTNPs/ECs based on weakly reactive Western blots, undetectable plasma viremia by a single copy assay, extremely low to undetectable HIV DNA levels, and difficult to isolate replication-competent virus. All 4 had at least one protective HLA allele and CD8(+) T-cell responses that were disproportionately high for the low antigen levels but comparatively lower than those of typical LTNPs/ECs. These unique persons exhibit extraordinary suppression over HIV replication, therefore, higher-level control than has been demonstrated in previous studies of LTNPs/ECs. Additional insight into the full spectrum of immune-mediated suppression over HIV replication may enhance our understanding of the associated mechanisms, which should inform the design of efficacious HIV vaccines and immunotherapies.